The Cancer Immunology Program is one of the longstanding components of the NYUCI, with 38 members from 9 Departments. This program has recently been expanded by the vigorous recruitment in Immunology conducted by the NYUCI and also the Department of Pathology, to new or newly renovated space. 12 faculty have been added to the Program in the past year;9 of these are new recruits brought to NYU School of Medicine from outstanding institutions such as Harvard, Stanford, Yale, UCSF, and others. Goals of the Cancer Immunology Program are: 1) to understand the biology of, more effectively diagnose, and develop treatments for neoplasms arising from cells of the lymphoid and myeloid system, 2) to understand the biology of tumor rejection, including the mechanisms used by tumors to evade the immune system;3) to effectively manipulate the immune system to promote immunotherapy of tumors. The program is subdivided into three thematic areas reflecting this tripartite mission. Members of this program collaborate extensively with other.NYUCI Programs, especially Growth Control, Breast Cancer, Neurooncology, and Melanoma. The Cancer Immunology Group has been highly productive, generating over 319 publications from 2002-2006 and has increased outside funding from $4.8 M in 2002 to $10.4 M in 2006. Total funding has increased from $7,128,048 to $11,674,122. Membership has increased from 17 to 38. Total publications for the past five years include 319 of which 4% are intra-programmatic and 15% are interprogrammatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-30
Application #
8038234
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
30
Fiscal Year
2010
Total Cost
$24,559
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Xu, Yang; Taylor, Paul; Andrade, Joshua et al. (2018) Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Res 78:6539-6548
Gagner, Jean-Pierre; Zagzag, David (2018) Probing Glioblastoma Tissue Heterogeneity with Laser Capture Microdissection. Methods Mol Biol 1741:209-220
Tsay, Jun-Chieh J; Wu, Benjamin G; Badri, Michelle H et al. (2018) Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. Am J Respir Crit Care Med 198:1188-1198
Martin, Patricia K; Marchiando, Amanda; Xu, Ruliang et al. (2018) Autophagy proteins suppress protective type I interferon signalling in response to the murine gut microbiota. Nat Microbiol 3:1131-1141
Coux, Rémi-Xavier; Teixeira, Felipe Karam; Lehmann, Ruth (2018) L(3)mbt and the LINT complex safeguard cellular identity in the Drosophila ovary. Development 145:
de la Parra, Columba; Ernlund, Amanda; Alard, Amandine et al. (2018) A widespread alternate form of cap-dependent mRNA translation initiation. Nat Commun 9:3068
Fanok, Melania H; Sun, Amy; Fogli, Laura K et al. (2018) Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma. J Invest Dermatol 138:1116-1125
Patibandla, Jay R; Fehniger, Julia E; Levine, Douglas A et al. (2018) Small cell cancers of the female genital tract: Molecular and clinical aspects. Gynecol Oncol 149:420-427
Harper, Lamia; Balasubramanian, Divya; Ohneck, Elizabeth A et al. (2018) Staphylococcus aureus Responds to the Central Metabolite Pyruvate To Regulate Virulence. MBio 9:
Berger, Ashton C; Korkut, Anil; Kanchi, Rupa S et al. (2018) A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33:690-705.e9

Showing the most recent 10 out of 1170 publications